RAAS Inhibitors

Women received RAS inhibitors less frequently than men overall in the analytic cohort. The ACE inhibitor prescription shortfall among women was not fully compensated by ARB2 substitution. All trial participants continue their existing ACE inhibitor or ARB dose unchanged for 28 weeks. RAASi eligibility in the model followed KDIGO 2012 criteria based on hypertension, type 2 diabetes, and UACR thresholds. RAAS inhibitor monotherapy has limited efficacy in reducing proteinuria. The study measured RAS inhibitor receipt as at least one dispensed box of an ACE inhibitor or ARB2 in the year before enrolment. The model assumed RAASi slows eGFR decline by 0.62 mL/min/1.73 m² per year compared with no RAASi. RAAS inhibitors reduce proteinuria by lowering intraglomerular pressure. RAAS inhibitor use carries risk in hypovolaemia, acute kidney injury, or hyperkalaemia. RAS inhibitors include ACE inhibitors and angiotensin II receptor blockers. US and European guidelines recommend RAS inhibitors as first-line antihypertensive therapy for patients with type 2 diabetes. Newly diagnosed eligible patients in both screening scenarios received RAASi treatment. RAAS inhibitors are the current standard…